MedTrace Logo

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

NCT00881946 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2012-04-04

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.

Conditions

Interventions

DRUG

GSK21110183

Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops

Sponsors & Collaborators

  • Accenture

    lead INDUSTRY

Principal Investigators

  • S. Jamie Freedman, MD, PhD

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Australia
  • Canada
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00881946 on ClinicalTrials.gov